Type 2 diabetes and glycemic control

Both type 1 and type 2 diabetes are independently associated with an increased risk for death among hospitalized patients with COVID-19, and a number of factors including poor glycemic control and BMI may predict mortality risk, suggest findings from two studies published in The Lancet Diabetes & Endocrinology.

The benefits and harms of intensive glucose control in people with type 2 diabetes may depend on which form of haptoglobin they have, shows an analysis of the ACCORD trial.

John Wilding comments on study results highlighting that imeglimin, an agent targeting mitochondrial bioenergetics, may represent a novel therapeutic approach for type 2 diabetes (2:17).

Imeglimin, an agent that improves mitochondrial function, has demonstrated potential as a novel treatment option for Japanese patients with type 2 diabetes in the phase III TIMES 1 and TIMES 3 trials.

Findings from the SUSTAIN 10 trial show that semaglutide results in better glycemic control than liraglutide when added to oral antidiabetic drugs in people with type 2 diabetes.

Treatment with the glucagon-like peptide-1 receptor agonist semaglutide results in better glycemic control than the sodium-glucose cotransporter 2 inhibitor canagliflozin among people with type 2 diabetes uncontrolled on metformin, indicate the SUSTAIN 8 trial results.

Adding an additional glucose-lowering medication is better than switching to a different one in people with type 2 diabetes, even if the original seemed to have little or no effect, shows an analysis from the MASTERMIND consortium.

The d-Nav system, which calculates insulin dose adjustments according to glucose levels, can help people with type 2 diabetes achieve larger reductions in glycated hemoglobin levels than with healthcare professional support alone, shows a randomized trial in The Lancet.

The hepatoselective glucokinase activator TTP399 reduces glycated hemoglobin levels without increasing the risk for hypoglycemia among patients with type 2 diabetes, suggest findings from the phase IIb AGATA trial.

A year of intensive periodontal treatment is associated with a significant reduction in glycated hemoglobin levels in patients with type 2 diabetes and moderate-to-severe periodontitis, UK researchers report.

A compound that stimulates the receptors for both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 has dose-dependent effects on glucose levels and bodyweight in people with type 2 diabetes.

Editorial Board member Lori Berard discusses how to meet and overcome the challenges that follow the initial insulin prescription in patients with type 2 diabetes (11:53).

Advisory Board member Katharine Barnard scrutinizes the opinion that clinicians should be relying on glycemic outcomes when weighing the decision to prescribe a diabetes device.

Carmen Soto and David Strain provide their insights on clinical inertia in diabetes care and present the co-production model of open communication as an innovative means to address this widespread clinical issue.

Zhu B et al. Acta Diabetol 2018. doi: 10.1007/s00592-018-1181-4

Mehtälä J et al. Diabetol Int 2018. doi: 10.1007/s13340-018-0360-4

Nishimura A et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0457-6

Editorial Board member Lori Berard talks through the stages and challenges associated with preparing type 2 diabetes patients for insulin therapy (9:00).

Deng Z et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0448-7

McDonnell ME. Curr Diab Rep 2018; 18: 42. doi: 10.1007/s11892-018-1015-3